You are viewing: US Recombinant Proteins Market analysis
Part of: Recombinant Proteins Market (Global)

The US Recombinant Proteins Market was valued at $312.5 Million in 2023 and projected to reach to $473.3 Million by 2028, representing a compound annual growth rate of 8.7%. The US recombinant proteins market is poised for sustained growth through 2028, driven by escalating demand for biologic therapeutics and continued innovation in protein engineering technologies.

US Recombinant Proteins Market (2023-2028) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Recombinant Proteins Market Trends and Insights

  • The US market is driven by robust biopharmaceutical innovation, increasing adoption of recombinant therapeutics, and strong healthcare infrastructure investment.
  • The US dominates North America's recombinant proteins sector, supported by leading research institutions, FDA regulatory frameworks, and substantial R&D spending by pharmaceutical companies. Growth in the US market is fueled by rising prevalence of chronic diseases, expanding biosimilar pipelines, and growing demand for personalized medicine.
  • The US recombinant proteins market benefits from advanced manufacturing capabilities and strategic partnerships between biotech firms and contract manufacturers.
  • Between 2023 and 2028, the US is expected to maintain its position as a key growth engine, driven by continued innovation in protein engineering and therapeutic applications across oncology, immunology, and rare diseases..

Key Market Statistics

  • CAGR (2023-2028) 8.7% CAGR
  • Market Size, 2023 ~USD 312.5 Million
  • Forecast, 2028 ~USD 473.3 Million
  • Country US

US Recombinant Proteins Market Overview

Market Valuation Growth :

The US recombinant proteins market reached $312.5 million in 2023 and is forecast to grow to $473.3 million by 2028, representing a robust 8.7% CAGR that outpaces the global average of 7.2%.

Biopharmaceutical Innovation Hub :

The US maintains its position as a global leader in recombinant protein development, driven by significant R&D investments from major pharmaceutical companies and biotechnology firms concentrated in regions like California, Massachusetts, and North Carolina.

Therapeutic Adoption Acceleration :

Increasing clinical adoption of recombinant therapeutics for oncology, immunology, and rare diseases is expanding the addressable market, supported by favorable FDA approval pathways and reimbursement policies.

Healthcare Infrastructure Investment :

Strong US healthcare spending, advanced manufacturing capabilities, and robust regulatory frameworks create an optimal environment for recombinant protein commercialization and market expansion.

US Recombinant Proteins Market Dynamics

  • Key growth catalysts include expanding applications in personalized medicine, increasing prevalence of chronic diseases, and rising investment in next-generation manufacturing platforms such as cell-free systems and continuous bioprocessing. Market dynamics will be shaped by competitive pressures from biosimilar development, evolving regulatory requirements, and the shift toward more cost-effective production methods.
  • Strategic partnerships between biopharmaceutical companies and contract manufacturing organizations (CMOs) will accelerate market penetration, while advances in recombinant protein quality and efficacy will drive adoption across therapeutic areas..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • The US recombinant proteins market reached $312.5 million in 2023 and will grow to $473.3 million by 2028 at an 8.7% CAGR.
    • The US market is propelled by strong biopharmaceutical R&D investment, FDA approval pathways, and increasing biosimilar adoption.
    • The US recombinant proteins sector benefits from advanced manufacturing infrastructure and strategic biotech partnerships.
    • The US market growth is supported by rising chronic disease prevalence and expanding therapeutic applications in oncology and immunology.

    Recombinant Proteins Market Report Scope

    Report Metric Details
    Base Year 2023
    Fastest Growing Segment INTERFERONS (IFNS) (Type)
    Forecast Period 2023-2028
    Growth Rate CAGR of 7.2% from 2023 to 2028
    Largest Segment PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES (End User)
    Market Size Base Year (Billions) ~USD 2.26 (2023)
    Revenue Forecast (Billions) ~USD 3.2 (2028)
    Segments Covered Product, Type, Application, Host Cell, End User

    US Recombinant Proteins Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Product

    • Adhesion Molecules & Receptors
    • Growth Factors & Chemokines
    • Immune Response Proteins
    • Kinase Proteins
    • Membrane Proteins
    • Other Recombinant Proteins
    • Recombinant Metabolic Enzymes
    • Regulatory Proteins
    • Structural Proteins

    By Type

    • Academic Research
    • Biologics
    • Biotechnology Research
    • Cell & Gene Therapy
    • Interferons (Ifns)
    • Interleukins (Ils)
    • Other Growth Factors & Chemokines
    • Vaccines

    By Application

    • Biopharmaceutical Production
    • Diagnostics
    • Drug Discovery & Development
    • Other Applications
    • Research

    By Host Cell

    • Bacterial Cells
    • Insect Cells
    • Mammalian Systems
    • Other Cell Hosts
    • Other Host Cells
    • Yeast & Fungi

    By End User

    • Academic Research Institutes
    • Biotechnology Companies
    • Contract Research Organizations
    • Other End Users
    • Pharmaceutical & Biopharmaceutical Companies

    US: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028

    Segment20212022202320242025202620272028CAGR (%)
    ACADEMIC RESEARCH INSTITUTES192.3198.6211.1226.2243.4262.9285.1309.58
    BIOTECHNOLOGY COMPANIES134.9139.2147.8158.1169.9183.2198.4215.27.8
    CONTRACT RESEARCH ORGANIZATIONS70.872.977.282.488.395102.6110.97.5
    OTHER END USERS48.249.151.554.457.861.565.870.56.5
    PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES376.6389.4414.7445479.5518.6563.3612.58.1
    TOTAL822.76849.11902.2966.031038.831121.171215.291318.637.9

    Target Audience

    • Biopharmaceutical Companies : US-based and international pharma firms need market sizing and growth forecasts to guide R&D investment decisions, pipeline prioritization, and commercial launch strategies for recombinant protein therapeutics.
    • Contract Manufacturing Organizations (CMOs) : CMOs and biotech manufacturers require US market intelligence to identify capacity expansion opportunities, negotiate client contracts, and position manufacturing capabilities in high-growth therapeutic segments.
    • Investment & Private Equity Firms : Investors evaluating biotech acquisitions, venture funding, or portfolio companies need validated US market data to assess growth potential, valuation benchmarks, and exit opportunities in recombinant proteins.
    • Healthcare Consultants & Advisors : Strategy consultants and business advisors serving pharma clients require US-specific market analysis to develop competitive strategies, market entry plans, and long-term business forecasts.
    • Regulatory & Policy Stakeholders : FDA officials, healthcare policymakers, and regulatory bodies benefit from market data to understand industry trends, assess manufacturing capacity, and inform reimbursement and approval policies.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise US market valuation ($312.5M in 2023) and verified 5-year forecast ($473.3M by 2028) to support investment decisions, business planning, and competitive positioning in the American recombinant proteins sector.
    • Regional Performance Benchmarking : Compare US market performance (8.7% CAGR) against global trends (7.2% CAGR) to identify growth acceleration opportunities and understand why the US market outpaces international competitors.
    • Therapeutic & Application Insights : Access detailed analysis of recombinant protein applications across US therapeutic areas including oncology, immunology, and rare diseases to identify high-growth segments and market entry opportunities.
    • Competitive Landscape Intelligence : Understand the US biopharmaceutical innovation ecosystem, key market players, manufacturing capabilities, and regulatory dynamics to inform go-to-market strategies and partnership development.
    • Strategic Decision Support : Leverage comprehensive US market data for M&A evaluation, product development prioritization, manufacturing site selection, and resource allocation across the American recombinant protein value chain.

    Frequently asked questions

    What is the current size of the US recombinant proteins market?

    The US recombinant proteins market was valued at $312.5 million in 2023 and is expected to reach $473.3 million by 2028.

    What is the growth rate of the US recombinant proteins market?

    The US recombinant proteins market is projected to grow at a compound annual growth rate (CAGR) of 8.7% from 2023 to 2028.

    What factors are driving growth in the US recombinant proteins market?

    Key drivers include rising chronic disease prevalence, expanding biosimilar pipelines, strong biopharmaceutical R&D investment, FDA regulatory support, and growing demand for personalized medicine in the US.

    Which therapeutic areas are leading the US recombinant proteins market?

    The US recombinant proteins market is experiencing strong growth in oncology, immunology, and rare disease therapeutics, supported by advanced protein engineering innovations.

    How does the US market compare to the global recombinant proteins market?

    The US recombinant proteins market grows at 8.7% CAGR, outpacing the global market's 7.2% CAGR, reflecting the US's leadership in biopharmaceutical innovation and healthcare infrastructure.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the current size of the recombinant proteins market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the recombinant proteins market. The secondary sources used for this study include The Antibody Society, Pharmaceutical Research and Manufacturers of America (PhRMA), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), American Medical Association (AMA), Recombinant Antibody Network (RAN) National Cancer Institute (NCI), Association of Medical Laboratory Immunologists (AMLI), American Society of Clinical Oncology (ASCO), United States Department of Agriculture (USDA), United States Food & Drug Administration (US FDA), American Association for Cancer Research (AACR), Biomolecular Interaction Network Database, European Medicines Agency (EMA), British Society for Immunology (BSI), Institute for Molecular Medicine, Annual Reports, SEC Filings, Press Releases, Company Websites, Investor Presentations, Magazines, Paid Databases, Expert Interviews, and MarketsandMarkets Analysis ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global recombinant proteins market, which was validated through primary research.

    Primary Research

    In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

    Recombinant proteins Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the recombinant proteins market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The major players in the industry and market have been identified through extensive primary and secondary research.
    • The revenues generated from the recombinant proteins service business of players operating in the market have been determined through secondary research and primary analysis.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

    Global Recombinant proteins Market Size :Bottom-Up Approach

    Recombinant proteins Market Size, and Share

    To know about the assumptions considered for the study, Request for Free Sample Report

    Top-Down Approach

    Recombinant proteins Market Size, and Share

    Data Triangulation

    After estimating the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    • Recombinant proteins are manipulated forms of proteins that are generated by recombinant DNA technology which modifies the gene sequences. These are formed by transfecting foreign genes into a host cell. They are primarily used to produce antibodies and enzymes for disease treatment, pharmaceutical products, protein-based polymers for drug delivery, and various other research & diagnostic uses.

    Key Stakeholders

    • Pharmaceutical and biotechnology companies
    • Life sciences companies
    • Academic research institutes
    • Government institutes
    • Private research firms
    • Contract Research Organizations (CROs)
    • Third-party suppliers, direct suppliers, distributors, and channel partners
    • Venture capitalists and investors
    • Market research and consulting firms

    Report Objectives

    • To define, describe, and forecast the recombinant proteins market by product, application, host cell, end user, and region.
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall recombinant proteins market
    • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), Middle East and Africa.
    • To profile the key players and analyze their market shares and core competencies2
    • To track and analyze competitive developments, such as acquisitions, product launches, expansions, agreements, partnerships and research & development activities.
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.

    Available Customizations

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

    Product Analysis

    • Product matrix, which provides a detailed comparison of the product portfolio of each company in the recombinant proteins Market

    Get the Full Recombinant Proteins Market Report

    Full forecast, segment splits, and company analysis for all Recombinant Proteins Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status